好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Pure Sensory Neuronopathy Associated with Plexin-D1 Antibody
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (5:00 PM-6:00 PM)
11-023

To report a novel case of pure sensory ganglionopathy/neuronopathy associated with plexin-D1 antibody.

Sensory neuronopathies are rare polyneuropathies characterized by degeneration of the dorsal root and trigeminal ganglia. Reported etiologies include autoimmune diseases, paraneoplastic syndromes, viral infections, vitamin B6 toxicity, and neurotoxic drug exposures. Plexin-D1 antibody has been associated with small fiber neuropathy and trigeminal neuropathy; however, its pathophysiological association with sensory neuronopathy remains incompletely understood.   

N/A

A 40-year-old woman presented with 4-week history of progressive numbness and paresthesia with subjective weakness involving all extremities. Clinical exam was notable for profound sensory deficits to pain, temperature, vibration, and proprioception in all limbs, with pseudoathetosis in the upper extremities, diffusely absent reflexes, malar rash, and Jaccoud’s arthropathy.

EMG/NCS results were consistent with a pure sensory neuronopathy with preserved motor responses. Sensory neuropathy/neuronopathy and small fiber panel was positive for plexin-D1 antibody. Anti-SSA and anti-TPO antibodies were positive. Vitamin B6, ANA, RF, anti-dsDNA, anti-Sm, and anti-SSB were normal. Vitamin B12 and B1 levels were initially low, and appropriate supplementation was given. Serology was negative for HIV, HTLV I/II, lyme, syphilis, and ganglioside panel. Paraneoplastic panel was non-contributory. CT chest, abdomen, pelvis, and PET scan showed no evidence of malignancy. MRI brain, cervical, thoracic, lumbar spine, and CSF studies were all unremarkable.

She was empirically treated with IVIG 2 g/kg. Due to concurrent suspicion for systemic lupus erythematosus (SLE), she was subsequently treated with azathioprine 100 mg oral daily and IV methylprednisolone with a prednisone taper. She reported subjective improvement in perceived weakness and sensory deficits.

Sensory neuronopathy is a rare presentation with limited etiologies, and clinical hallmarks of ataxia and non-length dependent sensory dysfunction. We report a novel case of sensory neuronopathy associated with plexin-D1 antibody affecting the limbs and trunk. This case highlights a unique clinical phenotype associated with plexin-D1 antibody. 

Authors/Disclosures
Christopher Hue, MD, PhD (University Hospital, Western University)
PRESENTER
Dr. Hue has nothing to disclose.
Emma Kaplan, MD (Mount Sinai Downtown Union Square) Dr. Kaplan has nothing to disclose.
Todd G. Rubin, MD, PhD Dr. Rubin has nothing to disclose.
Luke Kiefer, MD (Luke Kiefer) Dr. Kiefer has nothing to disclose.
Leslie D. Kerr, MD Dr. kerr has nothing to disclose.
Fred D. Lublin, MD, FAAN (Icahn School of Medicine At Mount Sinai) Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche/Genentech. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medimmune/Viela Bio/Horizon. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Receptos/Celgene/BMS. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Labcorp. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuralight. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Entelexo. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avotres. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Lublin has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Multiple entities. Dr. Lublin has stock in Avotres. Dr. Lublin has stock in Neuralight. The institution of Dr. Lublin has received research support from Brainstorm. The institution of Dr. Lublin has received research support from biogen. The institution of Dr. Lublin has received research support from NIH.
Susan Shin, MD (Mount Sinai Hospital) Dr. Shin has nothing to disclose.